Figure (Pegcetacoplan 01)
Syfovre Injection, Solution
Product Images NDC 73606-020
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Syfovre (NDC 73606-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Apellis Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure (Pegcetacoplan 02)
Figure (Pegcetacoplan 03)
Syfovre 15 mg/0.1 mL injection, solution in a small clear glass vial with a gray rubber stopper and silver cap, labeled for intravitreal use. The vial is plain without visible text or branding. Labeler: Apellis Pharmaceuticals, Inc.*
Figure (Pegcetacoplan 04)
Figure 1a (Pegcetacoplan 05)
An instructional black-and-white line drawing showing two hands positioned to open a small container or vial, likely demonstrating a step in preparing an intravitreal injection.*
Figure 1b (Pegcetacoplan 06)
Black and white line drawing showing a person holding a small vial with one hand and removing or placing the cap with the other hand, demonstrating how to handle an injection vial. No text or additional labeling is visible.*
Figure 2 (Pegcetacoplan 07)
An instructional line drawing depicting two hands holding a syringe. One hand holds the syringe barrel, and the other hand is twisting or attaching the syringe cap or needle cover, indicated by an arrow pointing to the interaction point.*
Figure 3a (Pegcetacoplan 08)
An instructional illustration depicting the preparation of an intravitreal injection. One gloved hand holds a vial or syringe component while the other hand pushes a plunger or stopper downwards. The image likely demonstrates a step in preparing Syfovre (pegcetacoplan) injection, 15 mg/0.1 mL, for administration.*
Figure 3b (Pegcetacoplan 09)
An instructional illustration showing a person drawing medication from a vial into a syringe. An inset highlights a close-up of the syringe needle entering the vial's rubber stopper, demonstrating the preparation of an intravitreal injectable solution.*
Figure 3c (Pegcetacoplan 10)
An instructional illustration showing a gloved hand holding a syringe filled with solution, with a close-up inset highlighting measurement markings on the syringe barrel. The illustration appears to demonstrate proper handling or measurement techniques for injection preparation.*
Figure 4 (Pegcetacoplan 11)
An instructional line drawing showing hands preparing a drug vial and syringe for injection, with an arrow indicating the rotation or removal of a component. The image visually guides step in the preparation or administration of an intravitreal injection.*
Figure 5 (Pegcetacoplan 12)
An illustration of a syringe marked with volume graduations up to 0.3 mL. A magnified circular inset highlights the 0.1 mL graduation on the syringe barrel. The image likely demonstrates the syringe volume measurement relevant to dosing.*
Chemical Formula (Pegcetacoplan 13)
Chemical structure of Pegcetacoplan, showing the molecular arrangement including amino acid residues and side chains, with detailed connections and labels for specific functional groups.*
Figure 1 (Pegcetacoplan 14)
Line graph showing the mean rate of change in GA lesion size (mm²) from baseline over 24 months. The x-axis represents visit months (Baseline, 6, 12, 18, 24), and the y-axis shows lesion size change with error bars. Three groups are compared: PM (202 subjects), PEOM (205 subjects), and Sham Pooled (207 subjects). Both PM and PEOM groups exhibit reduced lesion growth compared to Sham at month 24, with percentage reductions indicated (-21.9% for PM, -18.1% for PEOM).*
Figure 2 (Pegcetacoplan 15)
A line graph showing the mean rate of change from baseline in GA lesion size (mm²) over 24 months for three groups: PM, PEOM, and Sham Pooled. The x-axis represents visits at Baseline, 6, 12, 18, and 24 months, while the y-axis measures lesion change. The graph depicts lesion growth trends with percentage change labels for PEOM (-17.4%) and PM (-18.1%) at month 24.*
Principal Display Panel (15 mg Vial Carton)
The label for Syfovre (pegcetacoplan injection) shows a human prescription drug injection solution intended for intravitreal use. The strength is 15 mg per 0.1 mL of 150 mg/mL solution, supplied as one single-dose vial with instructions to discard unused portion. The labeler is Apellis Pharmaceuticals, and the NDC is 73606-020-01.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
